๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Risks and Benefits of Gene Therapy for Immunodeficiency: a Reality Check

โœ Scribed by Lemoine, N R

Book ID
110039226
Publisher
Nature Publishing Group
Year
2002
Tongue
English
Weight
53 KB
Volume
9
Category
Article
ISSN
0969-7128

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Gene therapy strategies for hemophilia:
Gene therapy strategies for hemophilia: benefits versus risks
โœ Inge Petrus; Marinee Chuah; Thierry VandenDriessche ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 167 KB

## Abstract Hemophilia is an inherited bleeding disorder caused by a deficiency of functional clotting factors VIII or IX in the blood plasma. The drawbacks of the classical protein substitution therapy fueled interest in alternative treatments by gene therapy. Hemophilia has been recognized as an

Benefits and risks of combination therap
Benefits and risks of combination therapy for hepatitis B
โœ Norah A. Terrault ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 102 KB

In successful antiviral therapy of hepatitis B, drug combinations, particularly combinations without cross-resistance, can delay or prevent the emergence of drug-resistant mutants. Because drug-resistant mutants are archived and may limit future therapeutic options, prevention is important for long-

Benefits and risks of interferon therapy
Benefits and risks of interferon therapy for hepatitis B
โœ Robert Perrillo ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 120 KB

Alpha interferon is the only licensed drug for hepatitis B with immunomodulatory as well as viral inhibitory properties. Potential advantages of interferon compared to nucleoside analogs include a lack of drug resistance, a finite and defined treatment course, and a higher likelihood for hepatitis B